Intercept Pharmaceuticals, Inc. (ICPT) — Financial statements
Income statement, balance sheet, and cash flow for Intercept Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 286↓21.4% | 363↑16.2% | 313↑24.1% | 252↑40.2% | 180 | |
| Cost of Revenue | 0.98↓68.3% | 3↓41.8% | 5↑26.4% | 4↑67.2% | 3 | |
| Gross Profit | 285↓21.0% | 360↑17.2% | 307↑24.0% | 248↑39.8% | 177 | |
| Operating Expenses | ||||||
| R&D Expenses | 177↓4.7% | 185↓3.2% | 191↓21.1% | 243↑17.1% | 207 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 255 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 176↓23.6% | 231↓30.6% | 332↑4.7% | 317↑24.2% | 255 | |
| Other Expenses | 0.00↓100.0% | 2↓51.2% | 4 | 0.00 | 0.00 | |
| Operating Expenses | 353↓15.2% | 416↓20.6% | 524↓6.5% | 560↑21.1% | 463 | |
| Total Costs & Expenses | 354↓15.6% | 419↓20.8% | 529↓6.2% | 564↑21.3% | 465 | |
| Operating Results | ||||||
| Operating Income | -68↓22.3% | -56↑74.3% | -217↑30.7% | -312↓9.4% | -285 | |
| Depreciation & Amortization | 7↑202.6% | 2↓51.2% | 4↓50.3% | 9↑94.0% | 5 | |
| EBITDA | -62↓77.0% | -35↑83.6% | -212↑28.0% | -295↓5.7% | -279 | |
| EBIT | -153↓314.7% | -37↑84.5% | -239↑21.4% | -304↓8.9% | -279 | |
| Interest & Other Income | ||||||
| Net Interest Income | -6↑11.7% | -7↑19.4% | -8↓5.9% | -8↑74.5% | -31 | |
| Interest Income | 16↓67.5% | 48↑20.0% | 40↑19.3% | 33 | 0.00 | |
| Interest Expense | 21↓60.7% | 54↑13.2% | 48↑16.8% | 41↑34.8% | 31 | |
| Non-Operating Income | 85↑554.7% | -19↓352.3% | 7↑183.6% | -9↓31.3% | -7 | |
| Other Income / Expenses | -107↓199.0% | -36↑18.3% | -44↓35.3% | -32↓35.8% | -24 | |
| Income Before Tax | -175↓91.3% | -91↑66.7% | -275↑20.3% | -345↓11.5% | -309 | |
| Income Tax Expense | -290↓641.1% | 54↑8.6% | 49↑6.4% | 46 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 115↑179.4% | -145↑55.3% | -324↑17.1% | -391↓26.5% | -309 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 115↑179.4% | -145↑55.3% | -324↑17.1% | -391↓26.5% | -309 | |
| Bottom-Line Net Income | 115↑179.4% | -145↑55.3% | -324↑17.1% | -391↓26.5% | -309 | |
| EPS (Basic) | 3.41↑174.9% | -4.55↑53.7% | -9.83↑20.4% | -12.35↓13.7% | -10.86 | |
| EPS (Diluted) | 3.40↑174.7% | -4.55↑53.7% | -9.83↑20.4% | -12.35↓13.7% | -10.86 | |
| Weighted Average Shares | 34↑6.2% | 32↓3.4% | 33↑4.2% | 32↑11.2% | 28 | |
| Weighted Average Diluted Shares | 34↑6.1% | 32↓3.3% | 33↑4.2% | 32↑11.2% | 28 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.